The world sits on the edge of their seats as we watch Cellceutix Corporation make leaps and bounds towards creating a drug that could potentially treat autism. Cellceutix is a preclinical cancer, anti-inflammatory, and autism drug developer that acquired the rights to a compound known as KM 391 in December, 2009. KM 391 is a molecule that was developed in India and will now be synthesized in the United States for testing. It is intended to be used as a treatment for autism, and there are currently no drugs on the market for such treatment.
Everyone from investors to researchers have been keeping a close eye on Cellceutix as they expedite the preliminary stages of testing with the backing of many organizations, awareness groups, and parents. Three stages of research with mice were conducted and the administering of KM 391 revealed a significant increase in serotonin uptake compared to the control group. Why is this significant? Many researchers argue that the equalization of serotonin uptake is an important development in the treatment of autism spectrum disorders.
The CEO of Cellceutix, George Evans, has been talking in length about the development of KM 391 and what this could potentially mean for the science and health care world. Mr. Evans was quoted saying,
“Autism is a condition where there is loss in certain brain functions, which leads to behavior disorder. The present scientific research directs us to a few things. One being the plasticity of brain tissue, the second being nerve tangling in the brain and the third being uneven production of serotonin, all which may have a significant effect on evolution and degree of severity of autism in any particular individual.”
Tests, completed by Cellceutix, on KM 391 also indicated that there may be no apparent side-effects in the long-term administration of KM 391 in mice. This type of information can help the drug maker in the process of becoming FDA approved, a step that they are currently en-route to. If development continues to render positive results, this could be a very big break in the fight to effectively treat autism.
For more information on Cellceutix, their preliminary lab results and KM 391, visit the company’s website: http://www.cellceutix.com